论文信息 - Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck. - 字舞流文

Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck.

A. Ganti | V. Bhatt

[1] G. Olson,et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. , 2013, Oral oncology.

[2] R. Kurzrock,et al. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3] D. Trafalis,et al. Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: from bench to bedside? , 2012, Anti-cancer drugs.

[4] A. Bozec,et al. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. , 2011, Oral oncology.

[5] D. Wong,et al. Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array Initiative , 2007, Clinical Cancer Research.

[6] Jacinto J. Regalado,et al. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma , 2005, International journal of experimental pathology.

[7] J. Ioannidis,et al. Prognostic Significance of Vascular Endothelial Growth Factor Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis , 2005, Clinical Cancer Research.